1.Non-alcoholic steatohepatitis and risk of hepatocellular carcinoma.
Rafael S RIOS ; Kenneth I ZHENG ; Ming-Hua ZHENG
Chinese Medical Journal 2021;134(24):2911-2921
The emergence of non-alcoholic fatty liver disease (NAFLD) as the leading chronic liver disease worldwide raises some concerns. In particular, NAFLD is closely tied to sedentary lifestyle habits and associated with other metabolic diseases, such as obesity and diabetes. At the end of the disease spectrum, non-alcoholic steatohepatitis (NASH) may progress to cirrhosis and hepatocellular carcinoma (HCC), representing a serious health problem to modern society. Recently, an increasing number of HCC cases originating from this progressive disease spectrum have been identified, with different levels of severity and complications. Updating the current guidelines by placing a bigger focus on this emerging cause and highlighting some of its unique features is necessary. Since, the drivers of the disease are complex and multifactorial, in order to improve future outcomes, having a better understanding of NASH progression into HCC may be helpful. The risks that can promote disease progression and currently available management strategies employed to monitor and treat NASH-related HCC make up the bulk of this review.
Carcinoma, Hepatocellular/etiology*
;
Humans
;
Liver Cirrhosis
;
Liver Neoplasms/etiology*
;
Non-alcoholic Fatty Liver Disease
;
Obesity
2.Protective association of Klotho rs495392 gene polymorphism against hepatic steatosis in non-alcoholic fatty liver disease patients
Wen-Yue LIU ; Xiaofang ZHANG ; Gang LI ; Liang-Jie TANG ; Pei-Wu ZHU ; Rafael S. RIOS ; Kenneth I. ZHENG ; Hong-Lei MA ; Xiao-Dong WANG ; Qiuwei PAN ; Robert J. DE KNEGT ; Luca VALENTI ; Mohsen GHANBARI ; Ming-Hua ZHENG
Clinical and Molecular Hepatology 2022;28(2):183-195
Background/Aims:
Non-alcoholic fatty liver disease (NAFLD) is closely associated with metabolic dysfunction. Among the multiple factors, genetic variation acts as important modifiers. Klotho, an enzyme encoded by the klotho (KL) gene in human, has been implicated in the pathogenesis of metabolic dysfunctions. However, the impact of variants in KL on NAFLD risk remains poorly understood. The aim of this study was to investigate the impact of KL rs495392 C>A polymorphism on the histological severity of NAFLD.
Methods:
We evaluated the impact of the KL rs495392 polymorphism on liver histology in 531 Chinese with NAFLD and replicated that in the population-based Rotterdam Study cohort. The interactions between the rs495392, vitamin D, and patatin-like phospholipase domain containing 3 (PNPLA3) rs738409 polymorphism were also analyzed.
Results:
Carriage of the rs495392 A allele had a protective effect on steatosis severity (odds ratio [OR], 0.61; 95% confidence interval [CI], 0.42–0.89; P=0.010) in Chinese patients. After adjustment for potential confounders, the A allele remained significant with a protective effect (OR, 0.66; 95% CI, 0.45–0.98; P=0.040). The effect on hepatic steatosis was confirmed in the Rotterdam Study cohort. Additional analysis showed the association between serum vitamin D levels and NAFLD specifically in rs495392 A allele carriers, but not in non-carriers. Moreover, we found that the rs495392 A allele attenuated the detrimental impact of PNPLA3 rs738409 G allele on the risk of severe hepatic steatosis.
Conclusions
The KL rs495392 polymorphism has a protective effect against hepatic steatosis in patients with NAFLD.
4.Hepatocyte apoptosis fragment product cytokeratin-18 M30 level and non-alcoholic steatohepatitis risk diagnosis: an international registry study.
Huai ZHANG ; Rafael S RIOS ; Jerome BOURSIER ; Rodolphe ANTY ; Wah-Kheong CHAN ; Jacob GEORGE ; Yusuf YILMAZ ; Vincent Wai-Sun WONG ; Jiangao FAN ; Jean-François DUFOUR ; George PAPATHEODORIDIS ; Li CHEN ; Jörn M SCHATTENBERG ; Junping SHI ; Liang XU ; Grace Lai-Hung WONG ; Naomi F LANGE ; Margarita PAPATHEODORIDI ; Yuqiang MI ; Yujie ZHOU ; Christopher D BYRNE ; Giovanni TARGHER ; Gong FENG ; Minghua ZHENG
Chinese Medical Journal 2023;136(3):341-350
BACKGROUND:
Liver biopsy for the diagnosis of non-alcoholic steatohepatitis (NASH) is limited by its inherent invasiveness and possible sampling errors. Some studies have shown that cytokeratin-18 (CK-18) concentrations may be useful in diagnosing NASH, but results across studies have been inconsistent. We aimed to identify the utility of CK-18 M30 concentrations as an alternative to liver biopsy for non-invasive identification of NASH.
METHODS:
Individual data were collected from 14 registry centers on patients with biopsy-proven non-alcoholic fatty liver disease (NAFLD), and in all patients, circulating CK-18 M30 levels were measured. Individuals with a NAFLD activity score (NAS) ≥5 with a score of ≥1 for each of steatosis, ballooning, and lobular inflammation were diagnosed as having definite NASH; individuals with a NAS ≤2 and no fibrosis were diagnosed as having non-alcoholic fatty liver (NAFL).
RESULTS:
A total of 2571 participants were screened, and 1008 (153 with NAFL and 855 with NASH) were finally enrolled. Median CK-18 M30 levels were higher in patients with NASH than in those with NAFL (mean difference 177 U/L; standardized mean difference [SMD]: 0.87 [0.69-1.04]). There was an interaction between CK-18 M30 levels and serum alanine aminotransferase, body mass index (BMI), and hypertension ( P < 0.001, P = 0.026 and P = 0.049, respectively). CK-18 M30 levels were positively associated with histological NAS in most centers. The area under the receiver operating characteristics (AUROC) for NASH was 0.750 (95% confidence intervals: 0.714-0.787), and CK-18 M30 at Youden's index maximum was 275.7 U/L. Both sensitivity (55% [52%-59%]) and positive predictive value (59%) were not ideal.
CONCLUSION
This large multicenter registry study shows that CK-18 M30 measurement in isolation is of limited value for non-invasively diagnosing NASH.
Humans
;
Non-alcoholic Fatty Liver Disease/diagnosis*
;
Keratin-18
;
Biomarkers
;
Biopsy
;
Hepatocytes/pathology*
;
Apoptosis
;
Liver/pathology*